The application potential of sintered beta-dicalcium pyrophosphate in total joint arthroplasty.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 12728430.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
An in vitro bone cell culture model was used to evaluate the potential application of sintered beta-dicalcium pyrophosphate (SDCP) in arthroplasty surgery. Primary osteoclasts and osteoblasts were cocultured with different sizes of SDCP particles. The changes in cell counts and the synthesis and secretion of alkaline phosphatase, acid phosphatase, and prostaglandin E(2) in response to the SDCP particles were monitored. When bone cells were cultured with SDCP particles smaller than 53 microm, both the osteoblast and osteoclast cell counts decreased significantly. When the SDCP particles were larger than 177 microm, although the osteoblast population increased significantly, the osteoclast population decreased significantly. Simultaneously, the titer of prostaglandin E(2) in the medium and the cytoplasmic prostaglandin E(2) increased significantly. We concluded that SDCP is a potentially useful bioceramic for the prevention of osteoclast-mediated periprosthetic osteolysis.
Medical subject headings
- Arthroplasty, Replacement
- Biocompatible Materials
- Bone Substitutes
- Calcium Pyrophosphate
- Osteoblasts
- Osteoclasts